Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T16:41:52.612Z.
Calculation as of: 2026-10-06T16:41:52.612Z.
Quote observation: 2026-10-06T16:40:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4140271b5ba2e17517ffa776ba39ee0784cb590c71b20d0313403f3757235181
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$1.15B
EV/Sales Ratio
22.86x
TTM Avg
24.63x
3Y Avg
10.61x
5Y Avg
10.20x
Market Cap
$1.15B
EV/Sales Ratio
1.77x
TTM Avg
1.60x
3Y Avg
2.60x
5Y Avg
4.51x
Market Cap
$1.13B
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
EV/Sales Ratio
2.18x
TTM Avg
2.15x
3Y Avg
3.23x
5Y Avg
3.44x
Market Cap
$1.21B
EV/Sales Ratio
3.79x
TTM Avg
4.64x
3Y Avg
5.92x
5Y Avg
9.62x
Market Cap
$1.22B
EV/Sales Ratio
1.22x
TTM Avg
1.20x
3Y Avg
1.00x
5Y Avg
1.05x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.17B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.15B | 22.86x | 24.63x | 10.61x | 10.20x |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 1.77x | 1.60x | 2.60x | 4.51x |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A | N/A | N/A | N/A |
| OPKO Health, Inc. (OPK)vs › | $1.13B | 2.08x | 1.76x | 1.62x | 1.49x |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 2.18x | 2.15x | 3.23x | 3.44x |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 4.88x | 6.64x | 6.66x | 5.94x |
| MannKind Corporation (MNKD)vs › | $1.21B | 3.79x | 4.64x | 5.92x | 9.62x |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 1.22x | 1.20x | 1.00x | 1.05x |
| Cronos Group Inc. (CRON)vs › | $1.22B | 3.36x | 1.73x | 1.52x | 2.69x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
